These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23613999)

  • 1. Natural killer KIR3DS1 is closely associated with HCV viral clearance and sustained virological response in HIV/HCV patients.
    Rivero-Juarez A; Gonzalez R; Camacho A; Manzanares-Martin B; Caruz A; Martinez-Peinado A; Torre-Cisneros J; Pineda JA; Peña J; Rivero A
    PLoS One; 2013; 8(4):e61992. PubMed ID: 23613999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients.
    Rivero-Juarez A; Camacho A; Caruz A; Neukam K; Gonzalez R; Di Lello FA; Perez-Camacho I; Mesa P; Torre-Cisneros J; Peña J; Pineda JA; Rivero A
    AIDS; 2012 May; 26(8):1009-15. PubMed ID: 22382144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism.
    Stenkvist J; Sönnerborg A; Weiland O
    J Viral Hepat; 2013 Mar; 20(3):193-9. PubMed ID: 23383658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy.
    Rivero-Juarez A; Neukam K; Labarga P; Camacho A; Macias J; Barreiro P; Torre-Cisneros J; Pineda JA; Soriano V; Rivero A
    J Infect; 2014 Apr; 68(4):372-7. PubMed ID: 24269677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The favorable effects of KIR3DS1 and Bw4(80Ile) on viral set point and CD4 count decline in HIV-1 patients with acutely infected with HIV-1 infection].
    Wang R; Liu Y; Lu XF; Liu ZY; Li Z; Zhang X
    Zhonghua Yi Xue Za Zhi; 2018 Sep; 98(35):2819-2823. PubMed ID: 30248785
    [No Abstract]   [Full Text] [Related]  

  • 6. KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.
    Umemura T; Ota M; Katsuyama Y; Wada S; Mori H; Maruyama A; Shibata S; Nozawa Y; Kimura T; Morita S; Joshita S; Komatsu M; Matsumoto A; Kamijo A; Kobayashi M; Takamatsu M; Yoshizawa K; Kiyosawa K; Tanaka E
    Hum Immunol; 2014 Aug; 75(8):822-6. PubMed ID: 24929144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.
    Neukam K; Barreiro P; Rivero-Juárez A; Caruz A; Mira JA; Camacho A; Macías J; Rivero A; Soriano V; Pineda JA
    J Infect; 2013 Jul; 67(1):59-64. PubMed ID: 23542783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals.
    Shea DO; Tuite H; Farrell G; Codd M; Mulcahy F; Norris S; Bergin C
    J Viral Hepat; 2008 Jul; 15(7):482-9. PubMed ID: 18221297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients.
    Aghemo A; Degasperi E; Rumi MG; Galmozzi E; Valenti L; De Francesco R; De Nicola S; Cheroni C; Grassi E; Colombo M
    Biomed Res Int; 2013; 2013():580796. PubMed ID: 23936821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
    Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
    J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy.
    Mandorfer M; Neukam K; Rivero A; Puoti M; Boesecke C; Baumgarten A; Grzeszczuk A; Zangerle R; Ernst D; Rockstroh JK; Trauner M; Pineda JA; Peck-Radosavljevic M; Reiberger T
    Antivir Ther; 2014; 19(4):407-14. PubMed ID: 24342953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection.
    Grebely J; Hellard M; Applegate T; Petoumenos K; Yeung B; Feld JJ; Rawlinson W; Lloyd AR; George J; Kaldor JM; Dore GJ; Matthews GV;
    AIDS; 2012 Aug; 26(13):1653-61. PubMed ID: 22555168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.
    Torres-Cornejo A; Ruiz-Valderas R; Jimenez-Jimenez L; Abad-Molina C; Gutierrez-Valencia A; Viciana P; Lopez-Cortes LF
    J Viral Hepat; 2014 Mar; 21(3):178-88. PubMed ID: 24438679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.
    Bruno R; Cariti G; Nasta P; Capetti A; Ravasio V; Galli M; Raise E; Palmieri G; Iannacone C; Puoti M
    Liver Int; 2015 Jan; 35(1):120-9. PubMed ID: 25041136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of control selection on sustained viral response rates in genotype 2/3 HCV mono-infected versus HIV/HCV co-infected patients.
    Nilsson J; Weiland O
    Scand J Infect Dis; 2010 Jul; 42(6-7):533-9. PubMed ID: 20214543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.
    Rallón NI; Soriano V; Naggie S; Restrepo C; Goldstein D; Vispo E; McHutchison J; Benito JM
    AIDS; 2011 May; 25(8):1025-33. PubMed ID: 21505315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
    Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
    World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
    Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
    Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
    Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
    Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.